Form 4: Hologic exec withholds shares for RSU taxes

Hologic’s International Group President Jan Verstreken had 196 shares withheld at $74.15 to cover taxes on vested RSUs, retaining 134,039 shares post-transaction.

Summary

• Jan Verstreken, Group President, International of Hologic, Inc. (HOLX), reported a tax withholding related to RSU vesting on 11/14/2025.
• A total of 196 shares of common stock were withheld (Transaction Code F) at a price of $74.15 per share to satisfy tax obligations.
• Post-transaction direct beneficial ownership stands at 134,039 shares.
• This was a withholding for taxes upon RSU settlement and not an open-market sale.
• No derivative securities transactions were reported.
• The report was signed on 11/18/2025 by Mark W. Irving, attorney-in-fact for Mr. Verstreken.

Sentiment

Score: 5

Explanation: Neutral, routine administrative insider transaction with minimal signaling value.

Positives

• Transaction reflects routine tax withholding upon RSU vesting, not an open-market sale, minimizing market impact.
• Executive retains a significant direct stake of 134,039 shares, aligning interests with shareholders.
• RSU vesting indicates ongoing execution of equity compensation programs.

Negatives

• Slight reduction in insider’s direct holdings by 196 shares due to tax withholding.

Future Outlook

No forward-looking statements or guidance were provided.

Management Comments

• Shares were withheld for tax obligations in connection with the settlement of restricted stock units for which service-based vesting requirements have been satisfied.

Industry Context

Insider share withholding for tax on RSU vesting is common in the medtech sector and broadly across large-cap U.S. companies; such administrative transactions typically have minimal signaling effect and limited price impact.

Comparison to Industry Standards

• Consistent with routine Form 4 filings at medtech peers (e.g., Boston Scientific (BSX), Abbott (ABT), Stryker (SYK)), where executives commonly settle tax liabilities via share withholding upon RSU vesting.
• No deviation from standard executive compensation and reporting practices observed; transaction size is immaterial relative to typical insider holdings in the sector.

Stakeholder Impact

• Minimal impact; routine RSU tax withholding with no operational effects stated.
• Executive continues to hold 134,039 shares, maintaining alignment with shareholders.

Next Steps

• No further actions disclosed.

Key Dates

Keywords

Hologic, HOLX, Form 4, insider transaction, restricted stock units, RSU vesting, tax withholding, beneficial ownership, Jan Verstreken, medical technology